Table 2.

Characteristics of cases of relapses of immune thrombocytopenia following COVID-19 vaccination

Characteristics	All cases (n = 17)	BNT162b2 (Pfizer-BioNTech, n = 12)	ChadOx1-S (AstraZeneca, n = 2)	mRNA-1273 (Moderna, n = 3)
Median age, y (minimum-maximum)	61 (22-87)	65 (22-87)	44 (25-63)	56 (50-62)
Women, n (%)	11 (64.7)	7 (63.6)	2 (100)	2 (66.3)
History of other autoimmune disease, n (%)	3 (17.6)^*	3 (25.0)	0	0
Splenectomized, n (%)	2 (11.8)	1 (8.3)	1 (50.0)	0
Dose
1, n (%)	12 (70.6)	7 (58.3)	2 (100)	3 (100.0)
2, n (%)	5 (29.4)	5 (41.7)	0	0
Median time to ITP onset, d (minimum-maximum)^†	5 (1-32)	6 (1-27)	12 (2-40)	2 (2-19)
Median lowest platelet count, ×10⁹/L (minimum-maximum)	6 (0-61)	8 (1-31)	33 (5-61)	13 (0-21)
Bleeding^†
No bleeding, n (%)	1 (5.9)	1 (8.3)	0	0
All bleeding, n (%)	15 (88.3)	10 (83.3)	2 (100)	3 (100)
Mouth bullae, n (%)	1 (5.9)	1 (8.3)	0	0
Epistaxis, n (%)	0	0	0	0
Hemoptysis, n (%)	0	0	0	0
Intracranial, n (%)	0	0	0	0
Evolution and treatment^‡
Spontaneous recovery, n (%)	3 (27.3)	2 (22.2)	1 (100)	0
Recovery after corticosteroids ± IVIG only, n (%)	6 (54.5)	6 (66.7)	0	0
Recovery after reintroduction of TPORA, n (%)	1 (9.1)	0	0	1 (100)
Recovery after need of vinblastine for refractory disease to corticosteroids, IVIG and TPORA, n (%)	1 (9.1)	1 (11.1)	0	0
Exposure to another dose of vaccine
Relapse of ITP, n	1	0	0	1
No relapse of ITP, n	2	2	0	0
Absence of subsequent exposure to the vaccine, n	6	6	0	0
Unknown, n	8	4	5	2

Abbreviations: ITP, immune thrombocytopenia; IVIG, intravenous immunoglobulin; TPORA, thrombopoietin receptor agonist.

2 patients with Graves’ disease and 1 with autoimmune hemolytic anemia (Evans’ syndrome).

^†

1 missing value (with BNT162b).

^‡

6 missing values (3 with BNT162b, 2 with ChadOx1-S, and 1 with mRNA-1273).